Acumen Pharmaceuticals (ABOS) Competitors $1.85 +0.05 (+2.78%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ABOS vs. GLUE, ESPR, TKNO, CDXC, ORGO, ZVRA, VERV, ARCT, CRVS, and SIGAShould you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include Monte Rosa Therapeutics (GLUE), Esperion Therapeutics (ESPR), Alpha Teknova (TKNO), ChromaDex (CDXC), Organogenesis (ORGO), Zevra Therapeutics (ZVRA), Verve Therapeutics (VERV), Arcturus Therapeutics (ARCT), Corvus Pharmaceuticals (CRVS), and SIGA Technologies (SIGA). These companies are all part of the "pharmaceutical products" industry. Acumen Pharmaceuticals vs. Monte Rosa Therapeutics Esperion Therapeutics Alpha Teknova ChromaDex Organogenesis Zevra Therapeutics Verve Therapeutics Arcturus Therapeutics Corvus Pharmaceuticals SIGA Technologies Acumen Pharmaceuticals (NASDAQ:ABOS) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, community ranking, dividends, earnings and risk. Is ABOS or GLUE more profitable? Acumen Pharmaceuticals' return on equity of -32.99% beat Monte Rosa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Acumen PharmaceuticalsN/A -32.99% -27.99% Monte Rosa Therapeutics N/A -62.68%-38.83% Which has more volatility and risk, ABOS or GLUE? Acumen Pharmaceuticals has a beta of -0.07, suggesting that its share price is 107% less volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500. Do institutionals and insiders hold more shares of ABOS or GLUE? 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 7.1% of Acumen Pharmaceuticals shares are held by insiders. Comparatively, 6.5% of Monte Rosa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media prefer ABOS or GLUE? In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 4 mentions for Monte Rosa Therapeutics and 3 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 0.97 beat Monte Rosa Therapeutics' score of -0.49 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monte Rosa Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate ABOS or GLUE? Acumen Pharmaceuticals currently has a consensus target price of $9.33, indicating a potential upside of 404.50%. Monte Rosa Therapeutics has a consensus target price of $14.00, indicating a potential upside of 102.02%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Acumen Pharmaceuticals is more favorable than Monte Rosa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acumen Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Monte Rosa Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has stronger earnings & valuation, ABOS or GLUE? Acumen Pharmaceuticals has higher earnings, but lower revenue than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcumen PharmaceuticalsN/AN/A-$52.37M-$1.38-1.34Monte Rosa Therapeutics$14.98M28.43-$135.35M-$1.83-3.79 Does the MarketBeat Community believe in ABOS or GLUE? Acumen Pharmaceuticals received 11 more outperform votes than Monte Rosa Therapeutics when rated by MarketBeat users. Likewise, 71.43% of users gave Acumen Pharmaceuticals an outperform vote while only 46.67% of users gave Monte Rosa Therapeutics an outperform vote. CompanyUnderperformOutperformAcumen PharmaceuticalsOutperform Votes2571.43% Underperform Votes1028.57% Monte Rosa TherapeuticsOutperform Votes1446.67% Underperform Votes1653.33% SummaryAcumen Pharmaceuticals beats Monte Rosa Therapeutics on 12 of the 16 factors compared between the two stocks. Ad Crypto 101 MediaThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABOS vs. The Competition Export to ExcelMetricAcumen PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$111.15M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E Ratio-1.3446.7389.9717.18Price / SalesN/A415.011,116.21116.99Price / CashN/A182.1042.8937.86Price / Book0.403.894.784.78Net Income-$52.37M-$42.21M$120.23M$225.60M7 Day Performance-8.87%-2.15%-1.92%-1.23%1 Month Performance-19.74%4.20%11.49%3.36%1 Year Performance-41.46%18.39%30.57%16.60% Acumen Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABOSAcumen Pharmaceuticals3.1582 of 5 stars$1.85+2.8%$9.33+404.5%-39.9%$111.15MN/A-1.3451Short Interest ↓News CoverageHigh Trading VolumeGLUEMonte Rosa Therapeutics1.9132 of 5 stars$7.65+1.2%$16.00+109.2%+28.3%$469.99M$14.98M-4.1390Analyst DowngradeNews CoverageESPREsperion Therapeutics3.9109 of 5 stars$2.38+5.8%$8.17+243.1%-3.5%$468.94M$295.45M-3.69240Analyst ForecastAnalyst RevisionNews CoverageTKNOAlpha Teknova0.4718 of 5 stars$8.79+9.5%$5.00-43.1%+124.1%$468.60M$36.68M-11.73240Gap UpCDXCChromaDex4.5929 of 5 stars$6.13+0.2%$8.00+30.5%+283.9%$468.23M$91.67M620.00106Analyst DowngradeORGOOrganogenesis4.2199 of 5 stars$3.52+3.5%$5.33+51.5%-20.6%$466.68M$433.14M-56.67950ZVRAZevra Therapeutics2.9108 of 5 stars$8.52+0.5%$21.00+146.5%+78.9%$454.76M$24.49M-4.3065Positive NewsVERVVerve Therapeutics1.9654 of 5 stars$5.36-6.1%$25.75+380.4%-57.7%$453.78M$11.76M-2.32110ARCTArcturus Therapeutics2.5569 of 5 stars$16.71-2.9%$66.75+299.5%-49.7%$452.62M$142.47M-7.75180Analyst ForecastNews CoverageCRVSCorvus Pharmaceuticals2.2299 of 5 stars$7.01-5.0%$12.83+83.1%+219.9%$450.44MN/A-7.8030Options VolumeNews CoverageHigh Trading VolumeSIGASIGA Technologies1.6071 of 5 stars$6.29+1.8%N/A+4.6%$449.11M$139.92M5.1540 Related Companies and Tools Related Companies GLUE Competitors ESPR Competitors TKNO Competitors CDXC Competitors ORGO Competitors ZVRA Competitors VERV Competitors ARCT Competitors CRVS Competitors SIGA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ABOS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABOS Stock Alerts